SG11202008977UA - Engineered immune effector cells and use thereof - Google Patents
Engineered immune effector cells and use thereofInfo
- Publication number
- SG11202008977UA SG11202008977UA SG11202008977UA SG11202008977UA SG11202008977UA SG 11202008977U A SG11202008977U A SG 11202008977UA SG 11202008977U A SG11202008977U A SG 11202008977UA SG 11202008977U A SG11202008977U A SG 11202008977UA SG 11202008977U A SG11202008977U A SG 11202008977UA
- Authority
- SG
- Singapore
- Prior art keywords
- effector cells
- immune effector
- engineered immune
- engineered
- cells
- Prior art date
Links
- 239000012642 immune effector Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464416—Receptors for cytokines
- A61K39/464419—Receptors for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464426—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5443—IL-15
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/52—Fibronectin; Laminin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862649781P | 2018-03-29 | 2018-03-29 | |
US201862774052P | 2018-11-30 | 2018-11-30 | |
PCT/US2018/067289 WO2019126748A1 (en) | 2017-12-22 | 2018-12-21 | Enhanced immune effector cells and use thereof |
PCT/US2019/024686 WO2019191495A1 (en) | 2018-03-29 | 2019-03-28 | Engineered immune effector cells and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202008977UA true SG11202008977UA (en) | 2020-10-29 |
Family
ID=68060556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202008977UA SG11202008977UA (en) | 2018-03-29 | 2019-03-28 | Engineered immune effector cells and use thereof |
Country Status (12)
Country | Link |
---|---|
US (1) | US20210024959A1 (en) |
EP (1) | EP3775228A4 (en) |
JP (1) | JP2021519061A (en) |
KR (1) | KR20200127250A (en) |
CN (1) | CN111954715A (en) |
AU (1) | AU2019243315A1 (en) |
BR (1) | BR112020019205A2 (en) |
CA (1) | CA3093020A1 (en) |
IL (1) | IL277611A (en) |
MX (1) | MX2020009896A (en) |
SG (1) | SG11202008977UA (en) |
WO (1) | WO2019191495A1 (en) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11866726B2 (en) | 2017-07-14 | 2024-01-09 | Editas Medicine, Inc. | Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites |
BR112020011017A2 (en) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | enhanced immune effector cells and their use |
CN110628821B (en) * | 2018-06-25 | 2022-02-18 | 首都医科大学宣武医院 | Cell model and preparation method and application thereof |
GB2617658B (en) | 2020-03-06 | 2024-04-17 | Metagenomi Inc | Class II, type V CRISPR systems |
US20230149511A1 (en) * | 2020-04-09 | 2023-05-18 | Wallkill BioPharma, Inc. | Treating autoimmune diseases with genetically modified cells |
EP4211244A1 (en) * | 2020-09-14 | 2023-07-19 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
CN114457025A (en) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing BTLA blocking substance or derivative thereof and application |
US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
CN114107211A (en) * | 2020-12-04 | 2022-03-01 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell and derivative thereof |
CN114645018A (en) * | 2020-12-18 | 2022-06-21 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell expressing CD38 targeted inhibitory factor, derivative and application thereof |
US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
CN114657137A (en) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell or derivative thereof for expressing BTLA-targeted shRNA and/or shRNA-miR |
CN114657133A (en) * | 2020-12-22 | 2022-06-24 | 未来智人再生医学研究院(广州)有限公司 | Pluripotent stem cell for expressing shRNA and/or shRNA-miR of targeted IL-4R alpha |
KR20230155521A (en) * | 2021-03-11 | 2023-11-10 | 카이트 파마 인코포레이티드 | Improved immune cell function |
WO2022256462A1 (en) * | 2021-06-02 | 2022-12-08 | Metagenomi, Inc. | Class ii, type v crispr systems |
CA3225985A1 (en) | 2021-07-01 | 2023-01-05 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
CN113278652B (en) * | 2021-07-20 | 2021-10-01 | 卡瑞济(北京)生命科技有限公司 | Application of CAR-T cell capable of increasing Survivin expression and IL-15 in preparation of antitumor drugs |
WO2023011651A1 (en) * | 2021-08-06 | 2023-02-09 | 上海驯鹿生物技术有限公司 | Fully humanized chimeric antigen receptor (car) for cd5 and cd7 dual targets, and use thereof |
WO2023023629A1 (en) * | 2021-08-18 | 2023-02-23 | Fate Therapeutics, Inc | Off-the-shelf ipsc-derived car-nk cell as monotherapy and in combination with antibody |
CN116103239A (en) * | 2021-11-11 | 2023-05-12 | 南京北恒生物科技有限公司 | Engineered immune cells and uses thereof |
TW202328437A (en) * | 2021-11-24 | 2023-07-16 | 中國大陸商杭州啟函生物科技有限公司 | Systems and methods for cell-based immunotherapies |
WO2023116929A1 (en) * | 2021-12-24 | 2023-06-29 | Hemacell Therapeutics Inc. | Method for producing human induced pluripotent stem cells through homologous recombination and integrase-mediated recombination |
CN116804185A (en) * | 2022-03-25 | 2023-09-26 | 士泽生物医药(苏州)有限公司 | Universal cell and preparation method thereof |
WO2023196994A1 (en) * | 2022-04-08 | 2023-10-12 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
CN114774469B (en) * | 2022-06-22 | 2022-11-08 | 南京艾尔普再生医学科技有限公司 | Method for preparing NK (Natural killer) cells with enhanced ADCC (advanced cellular cytotoxicity) function, NK cells and composition thereof |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
CN116286905B (en) * | 2023-05-11 | 2023-08-15 | 内蒙古大学 | Bovine-derived CRISPR/botAS 9 gene editing system, method and application |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
US5766944A (en) * | 1996-12-31 | 1998-06-16 | Ruiz; Margaret Eileen | T cell differentiation of CD34+ stem cells in cultured thymic epithelial fragments |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
JP2002060786A (en) | 2000-08-23 | 2002-02-26 | Kao Corp | Germicidal stainproofing agent for hard surface |
AU2002336373A1 (en) | 2001-08-20 | 2003-03-03 | The Scripps Research Institute | Zinc finger binding domains for cnn |
US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7754482B2 (en) | 2004-05-27 | 2010-07-13 | The Trustees Of The University Of Pennsylvania | Artificial antigen presenting cells and uses therefor |
NZ573646A (en) | 2006-06-12 | 2012-04-27 | Wyeth Llc | Single-chain multivalent binding proteins with effector function |
KR102110725B1 (en) | 2009-12-10 | 2020-05-13 | 리전츠 오브 더 유니버스티 오브 미네소타 | Tal effector-mediated dna modification |
ES2685171T3 (en) | 2010-06-14 | 2018-10-05 | The Scripps Research Institute | Reprogramming cells to a new destination |
WO2013019615A2 (en) | 2011-07-29 | 2013-02-07 | The Trustees Of The University Of Pennsylvania | Switch costimulatory receptors |
EP3594245A1 (en) | 2012-02-13 | 2020-01-15 | Seattle Children's Hospital d/b/a Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
EP3279315A3 (en) | 2012-05-25 | 2018-02-28 | Cellectis | Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells |
CN110423282B (en) | 2013-02-15 | 2023-09-08 | 加利福尼亚大学董事会 | Chimeric antigen receptor and methods of use thereof |
US9932607B2 (en) | 2013-11-15 | 2018-04-03 | The Board Of Trustees Of The Leland Stanford Junior University | Site-specific integration of transgenes into human cells |
MX2016010345A (en) * | 2014-02-14 | 2017-01-23 | Cellectis | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells. |
CN111849912B (en) | 2014-02-14 | 2024-03-15 | 贝里坤制药股份有限公司 | Method for activating T cells using inducible chimeric polypeptides |
CA2938887C (en) | 2014-02-14 | 2023-04-11 | Laurence J. N. Cooper | Chimeric antigen receptors and methods of making |
PT3122769T (en) | 2014-03-28 | 2023-04-24 | Univ Minnesota | Polypeptides, cells, and methods involving engineered cd16 |
CN107075483A (en) * | 2014-07-15 | 2017-08-18 | 朱诺治疗学股份有限公司 | The engineered cell treated for adoptive cellular |
AU2015312117A1 (en) | 2014-09-02 | 2017-03-02 | Bellicum Pharmaceuticals, Inc. | Costimulation of chimeric antigen receptors by Myd88 and CD40 polypeptides |
US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
RU2018107754A (en) * | 2015-08-11 | 2019-09-12 | Селлектис | CELLS FOR IMMUNOTHERAPY CREATED FOR TARGETING OF CD38 ANTIGEN AND FOR INACTIVATION OF CD38 GENE |
WO2017079673A1 (en) * | 2015-11-04 | 2017-05-11 | Fate Therapeutics, Inc. | Genomic engineering of pluripotent cells |
CA3007473A1 (en) | 2015-12-14 | 2017-06-22 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
WO2017127755A1 (en) * | 2016-01-20 | 2017-07-27 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
BR112020011017A2 (en) * | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | enhanced immune effector cells and their use |
-
2019
- 2019-03-28 SG SG11202008977UA patent/SG11202008977UA/en unknown
- 2019-03-28 EP EP19774331.3A patent/EP3775228A4/en active Pending
- 2019-03-28 MX MX2020009896A patent/MX2020009896A/en unknown
- 2019-03-28 KR KR1020207029206A patent/KR20200127250A/en unknown
- 2019-03-28 US US17/040,951 patent/US20210024959A1/en active Pending
- 2019-03-28 WO PCT/US2019/024686 patent/WO2019191495A1/en active Application Filing
- 2019-03-28 CN CN201980021676.XA patent/CN111954715A/en active Pending
- 2019-03-28 AU AU2019243315A patent/AU2019243315A1/en active Pending
- 2019-03-28 JP JP2020551264A patent/JP2021519061A/en active Pending
- 2019-03-28 BR BR112020019205-8A patent/BR112020019205A2/en unknown
- 2019-03-28 CA CA3093020A patent/CA3093020A1/en active Pending
-
2020
- 2020-09-24 IL IL277611A patent/IL277611A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP3775228A4 (en) | 2022-02-23 |
US20210024959A1 (en) | 2021-01-28 |
WO2019191495A1 (en) | 2019-10-03 |
JP2021519061A (en) | 2021-08-10 |
KR20200127250A (en) | 2020-11-10 |
CA3093020A1 (en) | 2019-10-03 |
AU2019243315A1 (en) | 2020-09-24 |
IL277611A (en) | 2020-11-30 |
BR112020019205A2 (en) | 2021-01-05 |
MX2020009896A (en) | 2020-10-12 |
EP3775228A1 (en) | 2021-02-17 |
CN111954715A (en) | 2020-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL277611A (en) | Engineered immune effector cells and use thereof | |
IL275177A (en) | Enhanced immune effector cells and use thereof | |
IL289830A (en) | Immune effector cell engineering and use thereof | |
IL274505A (en) | Novel engineered t cell receptors and immune therapy using the same | |
EP3680338A4 (en) | Genetically engineered t cell and application thereof | |
IL262772A (en) | Genetically engineered cells and methods of making the same | |
EP3707248A4 (en) | Modified immune cells and uses thereof | |
IL281113A (en) | Genetically engineered hematopoietic stem cells and uses thereof | |
IL267129A (en) | Novel t cell receptors and immune therapy using the same | |
IL269716A (en) | Antigen-specific immune effector cells | |
IL271751A (en) | Novel t cell receptors and immune therapy using the same | |
LT3500593T (en) | T cell receptors and immune therapy using the same | |
EP3964238A4 (en) | Bcma-targeting engineered immune cell and use thereof | |
SG11202011392VA (en) | Genetically engineered cell and application thereof | |
IL277673A (en) | Engineered cells and uses thereof | |
SG11202111679XA (en) | Engineered cells and uses thereof | |
EP4076448A4 (en) | Fluoroalkyl-oxadiazoles and uses thereof | |
EP3538551A4 (en) | Cd46-specific effector cells and uses thereof | |
EP3789486A4 (en) | Immune effector cell and use thereof | |
EP3373941A4 (en) | Modified immune cells and uses thereof | |
EP3791181A4 (en) | Immune age and use thereof | |
SG11202008008UA (en) | Universal antigen presenting cells and uses thereof | |
EP4036222A4 (en) | Modified immune cell and use thereof | |
SG11202108740UA (en) | Engineered immune cells | |
SG11202003404UA (en) | Novel engineered t cell receptors and immune therapy using the same |